Drug Profile
Research programme: liposomal cytotoxic compounds - TOT Biopharm
Alternative Names: TLD 208; TOT 201; TOT 202; TOT 203Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator TOT Biopharm
- Class Antineoplastics
- Mechanism of Action Cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Cancer; Colorectal cancer; Solid tumours
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Cancer in China (Liposomal)
- 25 Oct 2016 Preclinical trials in Cancer in China (unspecified route) (TOT Biopharm pipeline, October 2016)
- 16 Jul 2016 No recent reports of development identified for research development in Breast-cancer in China